WAYNE, Pa. -- (BUSINESS WIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care, urology and surgery, will present its ARROW® brand portfolio including PICCs and CVCs with Chlorag+ard® Technology, which provides antimicrobial and antithrombogenic protection, ARROW® VPS™ tip location system and the new EZ-IO® Needle + Stabilizer Kit at the World Congress on Vascular Access in Berlin, Germany on June 18-20, 2014.
At the WoCoVA on June 18-20, Teleflex will present innovative ARROW® brand products that are inspired by the goal of zero complications in vascular care. This includes protection against infection, thrombosis, occlusion and malposition.
At the booth, the Company will focus special attention on its Chlorag+ard technology. This includes ARROW® JACC with Chlorag+ard® technology, the world’s only antimicrobial and antithrombogenic CVC and ARROW PICC with Chlorag+ard Technology, the world’s only antimicrobial and antithrombogenic PICC. Additionally, the Company will highlight the new EZ-IO® needle and stabilizer kit as well as many educational innovations.
Three Symposia are scheduled, the first of which is to be held on Wednesday, June 18, 13:00h – 14:00h, under the title “Starting a Vascular Access Team. Why it makes sense and how to get started”. The Speakers will be Prof. Dr. Bernhard Gebauer, MD, PhD; Germany; Steve Hill, APRN; UK; Jim Lacy, BSN, RN, CRNI, VA-BC; U.S.A. - this symposium can be joined in WoCoVA room B05-06.
This will be followed by the second Symposium on Thursday, June 19, at 07:30h – 08:30h, in WoCoVA room B05-06, under the title “Antimicrobial Catheter Technologies – Fact or Fiction – A review of Safety, Cost-effectiveness and Efficiencies”. The speakers are: Dr. Giancarlo Scoppettuolo, MD, PhD, Italy; Kamna Giare-Patel; U.S.A.; Dr. Philippe Burtin, MD, PhD, France and Dr. Tanjew Stember, MD, PhD, Germany.
The third will take place on Thursday, June 19, 18:00 – 19:00, WoCoVA room B08-09, the title being “Global Clinical Updates on the Intraosseous route of Vascular Access”, with Chris Davlantes, MD, FACEP; U.S.A., speaking.
During the general sessions, the Company will provide additional information on catheter technologies, such as on the effectiveness of eluting technology or non-eluting technology in preventing thrombus accumulation and on the current role of central coated/treated catheters with antibacterial/antiseptic drugs.
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care, urology and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Wayne, PA, Teleflex employs approximately 11,400 people worldwide and serves healthcare providers in more than 150 countries. Additional information about Teleflex can be obtained from the company's website at teleflex.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, ARROW, VPS, EZ-IO, and Chlorag+ard are trademarks or registered trademarks of Teleflex Incorporated or its affiliates. ©2014 Teleflex Incorporated. All rights reserved.